Literature DB >> 17849465

Successful treatment of cytomegalovirus-associated hemophagocytic syndrome by intravenous immunoglobulins.

Arnaud Hot1, Marie Hélène Girard Madoux, Jean P Viard, Brigitte Coppéré, Jacques Ninet.   

Abstract

Virus-associated hemophagocytic syndrome (VAHS) is a rare complication in early cytomegalovirus (CMV) infection. There is no standard therapy for VAHS and the clinical course is variable. Data on the use of intravenous immunoglobulin (IVIG) in the treatment of CMV-associated VAHS are limited. We report a previously healthy, 32-year-old woman who presented with general malaise, fever, chills, and splenomegaly. Laboratory examination showed marked elevation of aminotransferase, leucopoenia, and thrombocytopenia. Acute CMV-infection was documented by the presence of immunoglobulin M anti-CMV and positive viremia in blood sample. Bone marrow examination revealed extensive hemophagocytosis. IVIG was administered after the diagnosis of CMV-associated VAHS. Her symptoms and laboratory abnormalities improved dramatically after the onset of the treatment and she did not require antiviral agent.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17849465     DOI: 10.1002/ajh.21008

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  16 in total

1.  Cytomegalovirus associated haemophagocytic lymphohistiocytosis in the immunocompetent adult managed according to HLH-2004 diagnostic using clinical and serological means only.

Authors:  M Atim-Oluk
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2013-03-13

2.  Forme Fruste of HLH (haemophagocytic lymphohistiocytosis): diagnostic and therapeutic challenges.

Authors:  Susumu Inoue; Chetna Mangat; Yaseen Rafe'e; Mahesh Sharman
Journal:  BMJ Case Rep       Date:  2015-01-29

Review 3.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

4.  Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B.

Authors:  Eileen A Larkin; Bradley G Stiles; Robert G Ulrich
Journal:  PLoS One       Date:  2010-10-11       Impact factor: 3.240

5.  Association of monoclonal expansion of Epstein-Barr virus-negative CD158a+ NK cells secreting large amounts of gamma interferon with hemophagocytic lymphohistiocytosis.

Authors:  María R López-Alvarez; María V Martínez-Sánchez; María G Salgado-Cecilia; José A Campillo; Damian Heine-Suñer; Florentina Villar-Permuy; José L Fuster; Agueda Bas; Juana Gil-Herrera; Manuel Muro; Ana M García-Alonso; María R Alvarez-López; Alfredo Minguela
Journal:  Clin Vaccine Immunol       Date:  2008-11-19

6.  Hemophagocytic lymphohistiocytosis syndrome associated with Epstein-Barr infection in an immunocompetent patient. A case study.

Authors:  Petros Ioannou; Evangelia Akoumianaki; Konstantinos Alexakis; Athanasia Proklou; Maria Psyllaki; Efthimis Stamatopoulos; Mairi Koulentaki; Eumorfia Kondili; Diamantis P Kofteridis
Journal:  Germs       Date:  2020-09-01

7.  Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases.

Authors:  Cheng-I Lin; Hsin-Hui Yu; Jyh-Hong Lee; Li-Chieh Wang; Yu-Tsan Lin; Yao-Hsu Yang; Bor-Luen Chiang
Journal:  Clin Rheumatol       Date:  2012-05-22       Impact factor: 3.650

8.  Concomitant Hemophagocytic Lymphohistiocytosis and Cytomegalovirus Disease: A Case Based Systemic Review.

Authors:  Linn Åsholt Rolsdorph; Knut Anders Mosevoll; Lars Helgeland; Håkon Reikvam
Journal:  Front Med (Lausanne)       Date:  2022-04-19

9.  Rare presentations of cytomegalovirus infection in renal allograft recipients.

Authors:  Mohammadreza Ardalan
Journal:  Nephrourol Mon       Date:  2012-03-01

Review 10.  Hemophagocytic lymphohistiocytosis: an update for nephrologists.

Authors:  Edward J Filippone; John L Farber
Journal:  Int Urol Nephrol       Date:  2016-04-20       Impact factor: 2.266

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.